Roche Holding AG (RHHBY)
| Previous close | 40.77 |
| Open | 39.35 |
| Bid | 40.71 x 40000 |
| Ask | 40.76 x 40000 |
| Day's range | 40.00 - 40.80 |
| 52-week range | 29.20 - 40.80 |
| Volume | |
| Avg. volume | 2,612,314 |
| Market cap | 262.012B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 20.18 |
| EPS (TTM) | 2.02 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 1.35 (3.31%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 38.59 |
Investor's Business DailyAstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.
ZacksRoche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
Roche (RHHBY) records impressive second-quarter and first-half 2024 performance on the back of strong demand for drugs and tests. Consequently, the company raises its annual earnings guidance.
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% Group sales growth accelerated to 9% (7% in CHF) in the second quarter as the decline in COVID-19-related sales no longer had an impact on overall salesPharmaceuticals Division sales rose by 5% in the first half; strong growth of 8% in the base business2 excluding COVID-19 effect
